28 results on '"Hobelsberger S"'
Search Results
2. Comparison of the efficacy of skin examination using 3D total body photography to clinical and dermoscopic examination
- Author
-
Gellrich, F.F., primary, Strunk, A., additional, Steininger, J., additional, Meier, F., additional, Beissert, S., additional, and Hobelsberger, S., additional
- Published
- 2024
- Full Text
- View/download PDF
3. A-234 - Comparison of the efficacy of skin examination using 3D total body photography to clinical and dermoscopic examination
- Author
-
Gellrich, F.F., Strunk, A., Steininger, J., Meier, F., Beissert, S., and Hobelsberger, S.
- Published
- 2024
- Full Text
- View/download PDF
4. Metastasiertes Plattenepithelkarzinom auf einem Ulkus bei Graft-versus-Host-Disease nach allogener Stammzelltransplantation
- Author
-
Hobelsberger, S., Meier, F., Beissert, S., and Abraham, S.
- Abstract
Wir berichten über einen 48-jährigen multimorbiden Patienten, der vor 26 Jahren eine allogene Knochenmarktransplantation aufgrund einer chronischen myeloischen Leukämie erhielt; 24 Jahre lang litt der Patient an einer sklerodermiformen chronischen Graft-versus-Host-Disease (GVHD) der Haut und der Lunge mit partieller Lungenresektion und immunsuppressiver Therapie. An den Unterschenkeln entwickelten sich rezidivierende Ulzerationen an den von der kutanen GVHD betroffenen Stellen. Der Patient stellte sich mit einem größenprogredienten Ulkus mit Therapieresistenz in unserer Klinik vor. Histologisch konnte ein Plattenepithelkarzinom diagnostiziert werden. Die Magnetresonanztomographie zeigte eine Knochenbeteiligung und eine kutane In-Transit-Metastase, und die Computertomographie ergab eine Metastase im Os sacrum. Bevor die Therapie eingeleitet wurde, verstarb der Patient plötzlich an den Folgen seiner Vorerkrankungen. Die Entwicklung einer kutanen GVHD ist häufig bei Patienten mit allogener Stammzelltransplantation. Hierbei ist das Risiko für die Entwicklung von Plattenepithelkarzinomen erhöht. Patienten sollten unter engmaschiger dermatologischer Kontrolle stehen. Bei Verdacht auf ein Plattenepithelkarzinom bei vorbestehender GVHD sollte zeitnah eine bioptische Sicherung erfolgen, um das Risiko einer Metastasierung zu senken.
- Published
- 2024
- Full Text
- View/download PDF
5. 348 Metabolic syndrome in psoriasis is associated with upregulation of CXCL16 on monocytes and a dysbalance in innate lymphoid cells
- Author
-
Schielke, L., primary, Zimmermann, N., additional, Hobelsberger, S., additional, Steininger, J., additional, Strunk, A., additional, Blau, K., additional, Künzel, S., additional, Beissert, S., additional, Abraham, S., additional, and Günther, C., additional
- Published
- 2022
- Full Text
- View/download PDF
6. Sewn-covering lamination for the instrument panel: from the discontinuous to the continuous process
- Author
-
Kurz, R., primary, Hobelsberger, S., additional, and Auer, H., additional
- Published
- 2017
- Full Text
- View/download PDF
7. Instrumententafel Nähkleid-Kaschierung – Vom diskontinuierlichen zum kontinuierlichen Prozess
- Author
-
Kurz, R., primary, Hobelsberger, S., additional, and Auer, H., additional
- Published
- 2017
- Full Text
- View/download PDF
8. Ex Vivo Confocal Microscopy Speeds up Surgical Margin Control of Re-Excised Skin Tumors and Greatly Shortens In-Hospital Stay.
- Author
-
Gellrich FF, Laske J, Steininger J, Eberl N, Meier F, Beissert S, and Hobelsberger S
- Abstract
Background/objectives: To ensure that non-melanoma skin cancer (NMSC) is completely removed in healthy tissue, micrographically controlled surgery (3D histology) is often performed, which can prolong the inpatient stay. This study examined ex vivo reflectance confocal microscopy (evRCM) for perioperative assessment of surgical margins, specifically in cases where re-excision was necessary due to incomplete removal of cutaneous tumor tissue., Methods: NMSC re-excisions were evaluated using evRCM by a cutaneous surgeon, with retrospective review by an independent pathologist when results differed from histology., Results: evRCM demonstrated high specificity (0.96; 95% CI, 0.90-0.99) but low sensitivity (0.20; 95% CI, 0.06-0.51). Unlike pathology, which discards outer surgical margins, evRCM examined the true surgical margins. Retrospective pathology analysis of the misdiagnosed cases confirmed that 25% ( n = 2/8) were false negative and 75% ( n = 6/8) were potentially false positive, resulting in a sensitivity of 0.2-0.8. Notably, evRCM led to a 113-day reduction in in-hospital stays, probably resulting in increased patient satisfaction and cost-effectiveness., Conclusions: evRCM was valuable for speeding up the assessment of surgical margins in patients with re-excised NMSC. Proper tissue preparation and assessment require interdisciplinary collaboration between cutaneous surgeons, pathologists, and physician assistants, emphasizing the need for standardized operating procedures.
- Published
- 2024
- Full Text
- View/download PDF
9. Prospective multicenter study using artificial intelligence to improve dermoscopic melanoma diagnosis in patient care.
- Author
-
Heinlein L, Maron RC, Hekler A, Haggenmüller S, Wies C, Utikal JS, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Korsing S, Berking C, Heppt MV, Erdmann M, Haferkamp S, Drexler K, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Krieghoff-Henning E, and Brinker TJ
- Abstract
Background: Early detection of melanoma, a potentially lethal type of skin cancer with high prevalence worldwide, improves patient prognosis. In retrospective studies, artificial intelligence (AI) has proven to be helpful for enhancing melanoma detection. However, there are few prospective studies confirming these promising results. Existing studies are limited by low sample sizes, too homogenous datasets, or lack of inclusion of rare melanoma subtypes, preventing a fair and thorough evaluation of AI and its generalizability, a crucial aspect for its application in the clinical setting., Methods: Therefore, we assessed "All Data are Ext" (ADAE), an established open-source ensemble algorithm for detecting melanomas, by comparing its diagnostic accuracy to that of dermatologists on a prospectively collected, external, heterogeneous test set comprising eight distinct hospitals, four different camera setups, rare melanoma subtypes, and special anatomical sites. We advanced the algorithm with real test-time augmentation (R-TTA, i.e., providing real photographs of lesions taken from multiple angles and averaging the predictions), and evaluated its generalization capabilities., Results: Overall, the AI shows higher balanced accuracy than dermatologists (0.798, 95% confidence interval (CI) 0.779-0.814 vs. 0.781, 95% CI 0.760-0.802; p = 4.0e-145), obtaining a higher sensitivity (0.921, 95% CI 0.900-0.942 vs. 0.734, 95% CI 0.701-0.770; p = 3.3e-165) at the cost of a lower specificity (0.673, 95% CI 0.641-0.702 vs. 0.828, 95% CI 0.804-0.852; p = 3.3e-165)., Conclusion: As the algorithm exhibits a significant performance advantage on our heterogeneous dataset exclusively comprising melanoma-suspicious lesions, AI may offer the potential to support dermatologists, particularly in diagnosing challenging cases., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
10. Patients' and dermatologists' preferences in artificial intelligence-driven skin cancer diagnostics: A prospective multicentric survey study.
- Author
-
Haggenmüller S, Maron RC, Hekler A, Krieghoff-Henning E, Utikal JS, Gaiser M, Müller V, Fabian S, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, Weichenthal M, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Korsing S, Berking C, Heppt MV, Erdmann M, Haferkamp S, Drexler K, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Kather JN, Fröhling S, Kaminski K, Doppler A, Bucher T, and Brinker TJ
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Dermatology methods, Prospective Studies, Surveys and Questionnaires statistics & numerical data, Artificial Intelligence, Dermatologists statistics & numerical data, Dermatologists psychology, Patient Preference statistics & numerical data, Skin Neoplasms diagnosis
- Abstract
Competing Interests: Conflicts of interest Dr Utikal is on the advisory board or has received honoraria from Amgen, Bristol Myers Squibb, GSK, Immunocore, LeoPharma, Merck Sharp and Dohme, Novartis, Pierre Fabre, Roche, and Sanofi outside the submitted work. Dr Meier has received speaker's fees or/and advisor's honoraria from Novartis, Roche, BMS, MSD, and Pierre Fabre. Dr Hobelsberger reports speaker's honoraria from Almirall, UCB, and AbbVie. Dr Gellrich has received speaker's fees or/and advisor's honoraria by Sun Pharma, Sanofi, and Merck. Dr Hauschild reports speaker's honoraria or consultancy fees from the following companies: Agenus, Amgen, BMS, Dermagnostix, Highlight Therapeutics, Immunocore, Incyte, IO Biotech, MerckPfizer, MSD, NercaCare, Novartis, Philogen, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme, Seagen, Sun Pharma, and Xenthera, outside the submitted work. Dr French is on the advisory board or has received consulting/speaker honoraria from for Galderma, Janssen, Leo Pharma, Eli Lilly, Almirall, Union Therapeutics, Regeneron, Novartis, Amgen, Abbvie, UCB, Biotest, and InflaRx. Dr Schlaak has received consultant or speaker fees or travel grants from BMS, MSD, Roche, Kyowa Kirin, Novartis, Sanofi Genzyme, Pierre Fabre, Sun Pharma, and Immunocore. Dr Erdmann declares honoraria from Bristol-Meyers Squibb, Immunocore, and Novartis outside the submitted work. Dr Haferkamp reports advisory roles for or has received honoraria from Pierre Fabre Pharmaceuticals, Novartis, Roche, BMS, Amgen, and MSD outside the submitted work. Dr Drexler has received honoraria from Pierre Fabre Pharmaceuticals and Novartis outside the submitted work. Dr Sondermann reports grants, speaker's honoraria, or consultancy fees from medi GmbH Bayreuth, Abbvie, Almirall, Amgen, Bristol-Myers Squibb, Celgene, GSK, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi Genzyme, and UCB outside the submitted work. Dr Schilling reports advisory roles for or has received honoraria from Pierre Fabre Pharmaceuticals, Incyte, Novartis, Roche, BMS, and MSD. Dr Goebeler has received speaker's honoraria and/or has served as a consultant and/or member of advisory boards for Almirall, Argenx, Biotest, Eli Lilly, Janssen Cilag, Leo Pharma, Novartis, and UCB, outside the submitted work. Dr Kather reports consulting services for Owkin, France, Panakeia, UK, and DoMore Diagnostics, Norway and has received honoraria for lectures by MSD, Eisai, and Fresenius. Dr Brinker reports owning a company that develops mobile apps (Smart Health Heidelberg GmbH, Handschuhsheimer Landstr. 9/1, 69120 Heidelberg). Author Haggenmüller, Author Maron, Author Hekler, Dr Krieghoff-Henning, Dr Gaiser, Dr Müller, Dr Fabian, Dr Sergon, Dr Weichenthal, Dr Heinzerling, Dr Schlager, Dr Ghoreschi, Dr Hilke, Dr Pochi, Dr Korsing, Dr Berking, Dr Heppt, Dr Schadendorf, Dr Fröhling, Author Kaminski, Author Doppler, and Author Bucher have no conflicts of interest to declare.
- Published
- 2024
- Full Text
- View/download PDF
11. Comparison of Extended Skin Cancer Screening Using a Three-Step Advanced Imaging Programme vs. Standard-of-Care Examination in a High-Risk Melanoma Patient Cohort.
- Author
-
Gellrich FF, Eberl N, Steininger J, Meier F, Beissert S, and Hobelsberger S
- Abstract
Modern diagnostic procedures, such as three-dimensional total body photography (3D-TBP), digital dermoscopy (DD), and reflectance confocal microscopy (RCM), can improve melanoma diagnosis, particularly in high-risk patients. This study assessed the benefits of combining these advanced imaging techniques in a three-step programme in managing high-risk patients. This study included 410 high-risk melanoma patients who underwent a specialised imaging consultation in addition to their regular skin examinations in outpatient care. At each visit, the patients underwent a 3D-TBP, a DD for suspicious findings, and an RCM for unclear DD findings. The histological findings of excisions initiated based on imaging consultation and outpatient care were compared. Imaging consultation detected sixteen confirmed melanomas (eight invasive and eight in situ) in 39 excised pigmented lesions. Outpatient care examination detected seven confirmed melanomas (one invasive and six in situ) in 163 excised melanocytic lesions. The number needed to excise (NNE) in the imaging consultation was significantly lower than that in the outpatient care (2.4 vs. 23.3). The NNE was 2.6 for DD and 2.3 for RCM. DD, 3D-TBP, or RCM detected melanomas that were not detected by the other imaging methods. The three-step imaging programme improves melanoma detection and reduces the number of unnecessary excisions in high-risk patients.
- Published
- 2024
- Full Text
- View/download PDF
12. Using multiple real-world dermoscopic photographs of one lesion improves melanoma classification via deep learning.
- Author
-
Hekler A, Maron RC, Haggenmüller S, Schmitt M, Wies C, Utikal JS, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Korsing S, Berking C, Heppt MV, Erdmann M, Haferkamp S, Drexler K, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Kather JN, Krieghoff-Henning E, and Brinker TJ
- Subjects
- Humans, Algorithms, Dermoscopy, Melanoma diagnostic imaging, Melanoma pathology, Deep Learning, Skin Neoplasms diagnostic imaging, Skin Neoplasms pathology
- Abstract
Competing Interests: Conflicts of interest Jochen S. Utikal is on the advisory board or has received honoraria and travel support from Amgen, Bristol Myers Squibb, GSK, Immunocore, LeoPharma, Merck Sharp and Dohme, Novartis, Pierre Fabre, Roche and Sanofi outside the submitted work. Friedegund Meier has received travel support and/or speaker's fees and/or advisor's honoraria by Novartis, Roche, BMS, MSD and Pierre Fabre and research funding from Novartis and Roche. Sarah Hobelsberger reports clinical trial support from Almirall and speaker's honoraria from Almirall, UCB and AbbVie and has received travel support from the following companies: UCB, Janssen Cilag, Almirall, Novartis, Lilly, LEO Pharma and AbbVie outside the submitted work. Sebastian Haferkamp reports advisory roles for or has received honoraria from Pierre Fabre Pharmaceuticals, Novartis, Roche, BMS, Amgen and MSD outside the submitted work. Konstantin Drexler has received honoraria from Pierre Fabre Pharmaceuticals and Novartis. Axel Hauschild reports clinical trial support, speaker's honoraria, or consultancy fees from the following companies: Agenus, Amgen, BMS, Dermagnostix, Highlight Therapeutics, Immunocore, Incyte, IO Biotech, MerckPfizer, MSD, NercaCare, Novartis, Philogen, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme, Seagen, Sun Pharma and Xenthera outside the submitted work. Lars E. French is on the advisory board or has received consulting/speaker honoraria from Galderma, Janssen, Leo Pharma, Eli Lilly, Almirall, Union Therapeutics, Regeneron, Novartis, Amgen, AbbVie, UCB, Biotest and InflaRx. Max Schlaak reports advisory roles for Bristol-Myers Squibb, Novartis, MSD, Roche, Pierre Fabre, Kyowa Kirin, Immunocore and Sanofi-Genzyme. Wiebke Sondermann reports grants, speaker's honoraria, or consultancy fees from medi GmbH Bayreuth, AbbVie, Almirall, Amgen, Bristol-Myers Squibb, Celgene, GSK, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi Genzyme and UCB outside the submitted work. Bastian Schilling reports advisory roles for or has received honoraria from Pierre Fabre Pharmaceuticals, Incyte, Novartis, Roche, BMS and MSD, research funding from BMS, Pierre Fabre Pharmaceuticals and MSD and travel support from Novartis, Roche, BMS, Pierre Fabre Pharmaceuticals and Amgen outside the submitted work. Matthias Goebeler has received speaker's honoraria and/or has served as a consultant and/or member of advisory boards for Almirall, Argenx, Biotest, Eli Lilly, Janssen Cilag, Leo Pharma, Novartis and UCB outside the submitted work. Michael Erdmann declares honoraria and travel support from Bristol-Meyers Squibb, Immunocore and Novartis outside the submitted work. Jakob N. Kather reports consulting services for Owkin, France, Panakeia, UK and DoMore Diagnostics, Norway and has received honoraria for lectures by MSD, Eisai and Fresenius. Titus J. Brinker reports owning a company that develops mobile apps (Smart Health Heidelberg GmbH, Handschuhsheimer Landstr. 9/1, 69,120 Heidelberg). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
13. Federated Learning for Decentralized Artificial Intelligence in Melanoma Diagnostics.
- Author
-
Haggenmüller S, Schmitt M, Krieghoff-Henning E, Hekler A, Maron RC, Wies C, Utikal JS, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Korsing S, Berking C, Heppt MV, Erdmann M, Haferkamp S, Drexler K, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Kather JN, Fröhling S, and Brinker TJ
- Subjects
- Humans, Artificial Intelligence, Retrospective Studies, Melanoma diagnosis, Dermatology, Skin Neoplasms diagnosis, Nevus diagnosis
- Abstract
Importance: The development of artificial intelligence (AI)-based melanoma classifiers typically calls for large, centralized datasets, requiring hospitals to give away their patient data, which raises serious privacy concerns. To address this concern, decentralized federated learning has been proposed, where classifier development is distributed across hospitals., Objective: To investigate whether a more privacy-preserving federated learning approach can achieve comparable diagnostic performance to a classical centralized (ie, single-model) and ensemble learning approach for AI-based melanoma diagnostics., Design, Setting, and Participants: This multicentric, single-arm diagnostic study developed a federated model for melanoma-nevus classification using histopathological whole-slide images prospectively acquired at 6 German university hospitals between April 2021 and February 2023 and benchmarked it using both a holdout and an external test dataset. Data analysis was performed from February to April 2023., Exposures: All whole-slide images were retrospectively analyzed by an AI-based classifier without influencing routine clinical care., Main Outcomes and Measures: The area under the receiver operating characteristic curve (AUROC) served as the primary end point for evaluating the diagnostic performance. Secondary end points included balanced accuracy, sensitivity, and specificity., Results: The study included 1025 whole-slide images of clinically melanoma-suspicious skin lesions from 923 patients, consisting of 388 histopathologically confirmed invasive melanomas and 637 nevi. The median (range) age at diagnosis was 58 (18-95) years for the training set, 57 (18-93) years for the holdout test dataset, and 61 (18-95) years for the external test dataset; the median (range) Breslow thickness was 0.70 (0.10-34.00) mm, 0.70 (0.20-14.40) mm, and 0.80 (0.30-20.00) mm, respectively. The federated approach (0.8579; 95% CI, 0.7693-0.9299) performed significantly worse than the classical centralized approach (0.9024; 95% CI, 0.8379-0.9565) in terms of AUROC on a holdout test dataset (pairwise Wilcoxon signed-rank, P < .001) but performed significantly better (0.9126; 95% CI, 0.8810-0.9412) than the classical centralized approach (0.9045; 95% CI, 0.8701-0.9331) on an external test dataset (pairwise Wilcoxon signed-rank, P < .001). Notably, the federated approach performed significantly worse than the ensemble approach on both the holdout (0.8867; 95% CI, 0.8103-0.9481) and external test dataset (0.9227; 95% CI, 0.8941-0.9479)., Conclusions and Relevance: The findings of this diagnostic study suggest that federated learning is a viable approach for the binary classification of invasive melanomas and nevi on a clinically representative distributed dataset. Federated learning can improve privacy protection in AI-based melanoma diagnostics while simultaneously promoting collaboration across institutions and countries. Moreover, it may have the potential to be extended to other image classification tasks in digital cancer histopathology and beyond.
- Published
- 2024
- Full Text
- View/download PDF
14. [Optical coherence tomography for the diagnosis and differentiation of cutaneous cysts: a case series].
- Author
-
Hobelsberger S, Gellrich FF, Steininger J, Beissert S, and Laske J
- Subjects
- Humans, Tomography, Optical Coherence, Epidermal Cyst diagnosis, Skin Neoplasms diagnosis, Hidrocystoma pathology, Sweat Gland Neoplasms pathology
- Abstract
Cutaneous cystic lesions (n = 35) were examined with optical coherence tomography. Cysts were visible as a hyporeflective roundish area with a clear margin; in some cases, the epidermis was thinned. Epidermal cysts, trichilemmal cysts, and hidrocystomas had a linear margin representing the epithelium of the cyst, whereas mucoid pseudocysts showed no linear margin. Trichilemmal and epidermal cysts presented with hyperreflective content that corresponds to keratin. By visualizing the margin and the content of the cyst, it was possible to differentiate between different types of cysts., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
15. Evaluating deep learning-based melanoma classification using immunohistochemistry and routine histology: A three center study.
- Author
-
Wies C, Schneider L, Haggenmüller S, Bucher TC, Hobelsberger S, Heppt MV, Ferrara G, Krieghoff-Henning EI, and Brinker TJ
- Subjects
- Humans, Immunohistochemistry, MART-1 Antigen, ROC Curve, Melanoma diagnosis, Deep Learning
- Abstract
Pathologists routinely use immunohistochemical (IHC)-stained tissue slides against MelanA in addition to hematoxylin and eosin (H&E)-stained slides to improve their accuracy in diagnosing melanomas. The use of diagnostic Deep Learning (DL)-based support systems for automated examination of tissue morphology and cellular composition has been well studied in standard H&E-stained tissue slides. In contrast, there are few studies that analyze IHC slides using DL. Therefore, we investigated the separate and joint performance of ResNets trained on MelanA and corresponding H&E-stained slides. The MelanA classifier achieved an area under receiver operating characteristics curve (AUROC) of 0.82 and 0.74 on out of distribution (OOD)-datasets, similar to the H&E-based benchmark classification of 0.81 and 0.75, respectively. A combined classifier using MelanA and H&E achieved AUROCs of 0.85 and 0.81 on the OOD datasets. DL MelanA-based assistance systems show the same performance as the benchmark H&E classification and may be improved by multi stain classification to assist pathologists in their clinical routine., Competing Interests: TJB would like to disclose that he is the owner of Smart Health Heidelberg GmbH (Handschuhsheimer Landstr. 9/1, 69120 Heidelberg, Germany) which develops mobile apps, outside of the submitted work. SHo reports clinical trial support from Almirall and speaker’s honoraria from Almirall, UCB and AbbVie and has received travel support from the following companies: UCB, Janssen Cilag, Almirall, Novartis, Lilly, LEO Pharma and AbbVie outside the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials., (Copyright: © 2024 Wies et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
16. Dermatologist-like explainable AI enhances trust and confidence in diagnosing melanoma.
- Author
-
Chanda T, Hauser K, Hobelsberger S, Bucher TC, Garcia CN, Wies C, Kittler H, Tschandl P, Navarrete-Dechent C, Podlipnik S, Chousakos E, Crnaric I, Majstorovic J, Alhajwan L, Foreman T, Peternel S, Sarap S, Özdemir İ, Barnhill RL, Llamas-Velasco M, Poch G, Korsing S, Sondermann W, Gellrich FF, Heppt MV, Erdmann M, Haferkamp S, Drexler K, Goebeler M, Schilling B, Utikal JS, Ghoreschi K, Fröhling S, Krieghoff-Henning E, and Brinker TJ
- Subjects
- Humans, Artificial Intelligence, Dermatologists, Diagnosis, Differential, Trust, Melanoma diagnosis
- Abstract
Artificial intelligence (AI) systems have been shown to help dermatologists diagnose melanoma more accurately, however they lack transparency, hindering user acceptance. Explainable AI (XAI) methods can help to increase transparency, yet often lack precise, domain-specific explanations. Moreover, the impact of XAI methods on dermatologists' decisions has not yet been evaluated. Building upon previous research, we introduce an XAI system that provides precise and domain-specific explanations alongside its differential diagnoses of melanomas and nevi. Through a three-phase study, we assess its impact on dermatologists' diagnostic accuracy, diagnostic confidence, and trust in the XAI-support. Our results show strong alignment between XAI and dermatologist explanations. We also show that dermatologists' confidence in their diagnoses, and their trust in the support system significantly increase with XAI compared to conventional AI. This study highlights dermatologists' willingness to adopt such XAI systems, promoting future use in the clinic., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
17. Clinician's Ability to Identify Non-Melanoma Skin Cancer on 3D-Total Body Photography Sectors that Were Initially Identified during In-Person Skin Examination with Dermoscopy.
- Author
-
Hobelsberger S, Steininger J, Laske J, Berndt K, Meier F, Beissert S, and Gellrich FF
- Subjects
- Humans, Female, Male, Dermoscopy methods, Photography, Skin Neoplasms diagnostic imaging, Skin Neoplasms pathology, Melanoma diagnostic imaging, Melanoma pathology, Carcinoma, Basal Cell diagnostic imaging, Carcinoma, Basal Cell pathology
- Abstract
Introduction: Non-melanoma skin cancer (NMSC) is a cause of significant morbidity and mortality in high-risk individuals. Total body photography (TBP) is currently used to monitor melanocytic lesions in patients with high risk for melanoma. The authors examined if three-dimensional (3D)-TBP could be useful for diagnosis of NMSC., Methods: Patients (n = 129; 52 female, 77 male) with lesions suspicious for NMSC who had not yet had a biopsy underwent clinical examination followed by examination of each lesion with 3D-TBP Vectra®WB360 (Canfield Scientific, Parsippany, NJ, USA) and dermoscopy., Results: The 129 patients had a total of 182 lesions. Histological examination was performed for 158 lesions; the diagnoses included basal cell carcinoma (BCC; n = 107), squamous cell carcinoma (SCC; n = 27), in-situ SCC (n = 15). Lesions were located in the head/neck region (n = 138), trunk (n = 21), and limbs (n = 23). Of the 182 lesions examined, 12 were not visible on 3D-TBP; reasons for not being visible included location under hair and on septal of nose. Two lesions appeared only as erythema in 3D-TBP but were clearly identifiable on conventional photographs. Sensitivity of 3D-TBP was lower than that of dermoscopy for BCC (73% vs. 79%, p = 0.327), higher for SCC (81% vs. 74%, p = 0.727), and lower for in-situ SCC (0% vs. 33%, p = 125). Specificity of 3D-TBP was lower than that of dermoscopy for BCC (77% vs. 82%, 0.581), lower for SCC (75% vs. 84%, p = 0.063), and higher for in-situ SCC (97% vs. 94%, p = 0.344). Diagnostic accuracy of 3D-TBP was lower than that of dermoscopy for BCC (75% vs. 80%), lower for SCC (76% vs. 82%), and lower for in-situ SCC (88% vs. 89%). Lesion location was not associated with diagnostic confidence in dermoscopy (p = 0.152) or 3D-TBP (p = 0.353). If only lesions with high confidence were included in the calculation, diagnostic accuracy increased for BCC (n = 27; sensitivity 85%, specificity 85%, diagnostic accuracy 85%), SCC (n = 10; sensitivity 90%, specificity 80%, diagnostic accuracy 83%), and for in-situ SCC (n = 2; sensitivity 0%, specificity 100%, diagnostic accuracy 95%)., Conclusion: Diagnostic accuracy appears to be slightly lower for 3D-TBP in comparison to dermoscopy. However, there is no statistically significant difference in the sensitivity and specificity of 3D-TBP and dermoscopy for NMSC. Diagnostic accuracy increases, if only lesions with high confidence are included in the calculation. Further studies are necessary to determine if 3D-TBP can improve management of NMSC., (© 2023 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
18. Line-field confocal optical coherence tomography for the diagnosis of onychomycosis in comparison with healthy nails: A case series.
- Author
-
Hobelsberger S, Steininger J, Bauer A, Beissert S, and Gellrich FF
- Subjects
- Humans, Nails diagnostic imaging, Tomography, Optical Coherence methods, Microscopy, Confocal, Onychomycosis diagnostic imaging
- Published
- 2023
- Full Text
- View/download PDF
19. Model soups improve performance of dermoscopic skin cancer classifiers.
- Author
-
Maron RC, Hekler A, Haggenmüller S, von Kalle C, Utikal JS, Müller V, Gaiser M, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Korsing S, Berking C, Heppt MV, Erdmann M, Haferkamp S, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Kather JN, Fröhling S, Lipka DB, Krieghoff-Henning E, and Brinker TJ
- Subjects
- Dermoscopy methods, Humans, Sensitivity and Specificity, Melanoma, Cutaneous Malignant, Melanoma diagnostic imaging, Skin Neoplasms diagnostic imaging
- Abstract
Background: Image-based cancer classifiers suffer from a variety of problems which negatively affect their performance. For example, variation in image brightness or different cameras can already suffice to diminish performance. Ensemble solutions, where multiple model predictions are combined into one, can improve these problems. However, ensembles are computationally intensive and less transparent to practitioners than single model solutions. Constructing model soups, by averaging the weights of multiple models into a single model, could circumvent these limitations while still improving performance., Objective: To investigate the performance of model soups for a dermoscopic melanoma-nevus skin cancer classification task with respect to (1) generalisation to images from other clinics, (2) robustness against small image changes and (3) calibration such that the confidences correspond closely to the actual predictive uncertainties., Methods: We construct model soups by fine-tuning pre-trained models on seven different image resolutions and subsequently averaging their weights. Performance is evaluated on a multi-source dataset including holdout and external components., Results: We find that model soups improve generalisation and calibration on the external component while maintaining performance on the holdout component. For robustness, we observe performance improvements for pertubated test images, while the performance on corrupted test images remains on par., Conclusions: Overall, souping for skin cancer classifiers has a positive effect on generalisation, robustness and calibration. It is easy for practitioners to implement and by combining multiple models into a single model, complexity is reduced. This could be an important factor in achieving clinical applicability, as less complexity generally means more transparency., Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: JSU is on the advisory board or has received honoraria and travel support from Amgen, Bristol Myers Squibb, GSK, Immunocore, LeoPharma, Merck Sharp and Dohme, Novartis, Pierre Fabre, Roche, outside the submitted work. FM has received travel support or/and speaker's fees or/and advisor's honoraria by Novartis, Roche, BMS, MSD and Pierre Fabre and research funding from Novartis and Roche. SH reports advisory roles for or has received honoraria from Pierre Fabre Pharmaceuticals, Novartis, Roche, BMS, Amgen and MSD outside the submitted work. Axel H. reports clinical trial support, speaker's honoraria, or consultancy fees from the following companies: Amgen, BMS, Merck Serono, MSD, Novartis, Oncosec, Philogen, Pierre Fabre, Provectus, Regeneron, Roche, OncoSec, Sanofi-Genzyme, and Sun Pharma, outside, the submitted work. LF is on the advisory board or has received consulting/speaker honoraria from for Galderma, Janssen, Leo Pharma, Eli Lilly, Almirall, Union Therapeutics, Regeneron, Novartis, Amgen, Abbvie, UCB, Biotest, and InflaRx. MS reports advisory roles for Bristol-Myers Squibb, Novartis, MSD, Roche, Pierre Fabre, Kyowa Kirin, Immunocore and Sanofi-Genzyme. WS reports grants, speaker's honoraria or consultancy fees from medi GmbH Bayreuth, Abbvie, Almirall, Amgen, Bristol-Myers Squibb, Celgene, GSK, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi Genzyme and UCB outside the submitted work. BS reports advisory roles for or has received honoraria from Pierre Fabre Pharmaceuticals, Incyte, Novartis, Roche, BMS and MSD, research funding from BMS, Pierre Fabre Pharmaceuticals and MSD, and travel support from Novartis, Roche, BMS, Pierre Fabre Pharmaceuticals and Amgen; outside the submitted work. MG has received speaker's honoraria and/or has served as a consultant and/or member of advisory boards for Almirall, Argenx, Biotest, Eli Lilly, Janssen Cilag, Leo Pharma, Novartis and UCB, outside the submitted work. TJB is the owner of Smart Health Heidelberg GmbH (Handschuhsheimer Landstr. 9/1, 69120 Heidelberg, Germany, https://smarthealth.de) which develops telemedicine mobile apps (such as AppDoc; https://online-hautarzt.net and Intimarzt; https://intimarzt.de), outside of the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
20. Metabolic Syndrome in Psoriasis Is Associated With Upregulation of CXCL16 on Monocytes and a Dysbalance in Innate Lymphoid Cells.
- Author
-
Schielke L, Zimmermann N, Hobelsberger S, Steininger J, Strunk A, Blau K, Hernandez J, Künzel S, Ziegenbalg R, Rösing S, Beissert S, Abraham S, and Günther C
- Subjects
- Chemokine CXCL16 metabolism, Humans, Immunity, Innate, Lymphocytes, Monocytes, Obesity metabolism, Up-Regulation, Metabolic Syndrome metabolism, Psoriasis
- Abstract
Psoriasis is frequently associated with the metabolic syndrome and occurs more often in obese individuals. In order to understand innate immune mechanisms mediating this inflammatory pattern we investigated expression of the chemokine and lipid scavenger receptor CXCL16 in patients with psoriasis and associated comorbidities. CXCL16 expression was enhanced on all monocyte subsets in psoriatic patients compared with healthy controls and positively correlated with psoriasis activity and severity index, body mass index and the risk for cardiovascular disease indicated by PROCAM score. The intensity of CXCL16 expression on monocytes further correlated with their capability to phagocytose oxidized LDL indicating the possibility to transform into foam cells in atherosclerotic plaques. Patients with psoriasis and atherosclerosis or obesity displayed elevated numbers of innate lymphoid cells in blood with specific increase of the IFN-γ or IL-17 producing ILC1 and ILC3 subpopulations. The expression of the CXCL16 receptor, CXCR6, was increased in ILCs and co-expressed with CCR6 but not CCR7 indicating their migratory potential to psoriatic skin or adipose tissue that is characterized by strong CXCL16 and CCL20 expression. This hypothesis was supported by the finding that the percentage of CXCR6 expressing ILCs was alleviated in blood of psoriatic patients. Together these data link a strong expression of CXCL16 to metabolic syndrome in psoriasis and indicate a possible link to ILC activation and tissue distribution in obese psoriatic patients. These data contribute to the understanding of the complex interaction of innate immunity and metabolic state in psoriasis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Schielke, Zimmermann, Hobelsberger, Steininger, Strunk, Blau, Hernandez, Künzel, Ziegenbalg, Rösing, Beissert, Abraham and Günther.)
- Published
- 2022
- Full Text
- View/download PDF
21. Obstructive sleep apnoea is associated with the development of diastolic dysfunction after myocardial infarction with preserved ejection fraction.
- Author
-
Buchner S, Wester M, Hobelsberger S, Fisser C, Debl K, Hetzenecker A, Hamer OW, Zeman F, Maier LS, and Arzt M
- Subjects
- Humans, Polysomnography methods, Stroke Volume, Ventricular Function, Left, Myocardial Infarction complications, Sleep Apnea Syndromes complications, Sleep Apnea, Obstructive complications
- Abstract
Background: Left ventricular diastolic dysfunction is a predictor of adverse outcome after acute myocardial infarction (AMI). We aimed to test if sleep-disordered breathing (SDB) contributes to the development of diastolic dysfunction in patients with preserved left ventricular ejection fraction after AMI., Method: Patients with AMI, percutaneous coronary intervention and an ejection fraction ≥50% were included in this sub-analysis of a prospective observational study. Patients with AMI (n = 41) underwent cardiovascular magnetic resonance imaging (volume-time curve analysis) to define diastolic function by means of the normalised peak filling rate [nPFR; (end diastolic volume/second)]. In patients with AMI, the nPFR was assessed within <5 days and three months after AMI. Patients with AMI were stratified in patients with (apnoea-hypopnoea index, AHI ≥15/h) and without (AHI <15/h) SDB as assessed by polysomnography., Results: At the time of AMI, the nPFR was similar between patients with and without SDB (2.90 ± 0.54 vs. 3.03 ± 1.20, p = 0.662). Within three months after AMI, diastolic function was significantly lower in patients with SDB than in patients without SDB (ΔnPFR: -0.83 ± 0.14 vs. 0.03 ± 0.14; p < 0.001; ANCOVA, adjusted for baseline nPFR). In contrast to central AHI, obstructive AHI was associated with a lower nPFR three months after AMI, after accounting for established risk factors for diastolic dysfunction [multiple linear regression analysis, B (95%CI): -0.036 (-0.063 to -0.009), p = 0.011]., Conclusion: Our data indicate that obstructive sleep apnoea impairs diastolic function early after myocardial infarction., (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
22. [Successful treatment of cutaneous leishmaniasis with simulated daylight photodynamic therapy].
- Author
-
Hobelsberger S, Krauß MP, Bogdan C, and Aschoff R
- Subjects
- Aminolevulinic Acid therapeutic use, Child, Preschool, Humans, Male, Pain, Leishmania tropica, Leishmaniasis, Cutaneous diagnosis, Leishmaniasis, Cutaneous drug therapy, Photochemotherapy
- Abstract
A 5-year-old Syrian boy , presented with a complex cutaneous leishmaniasis (CL) of the right ankle caused by Leishmania (L.) tropica. The patient received photodynamic therapy (PDT; 6 cycles with application of 5‑aminolevulinic acid and foil occlusion for 3 h). Due to pain during exposure to red light, exposure was continued with simulated daylight (sDL-PDT). The lesion healed with an atrophic scar. Due to fewer side effects and less pain, sDL-PDT seems to be a good therapeutic strategy for CL caused by L. tropica., (© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
23. Explainable artificial intelligence in skin cancer recognition: A systematic review.
- Author
-
Hauser K, Kurz A, Haggenmüller S, Maron RC, von Kalle C, Utikal JS, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Kutzner H, Berking C, Heppt MV, Erdmann M, Haferkamp S, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Kather JN, Fröhling S, Lipka DB, Hekler A, Krieghoff-Henning E, and Brinker TJ
- Subjects
- Algorithms, Humans, Neural Networks, Computer, Artificial Intelligence, Skin Neoplasms diagnosis
- Abstract
Background: Due to their ability to solve complex problems, deep neural networks (DNNs) are becoming increasingly popular in medical applications. However, decision-making by such algorithms is essentially a black-box process that renders it difficult for physicians to judge whether the decisions are reliable. The use of explainable artificial intelligence (XAI) is often suggested as a solution to this problem. We investigate how XAI is used for skin cancer detection: how is it used during the development of new DNNs? What kinds of visualisations are commonly used? Are there systematic evaluations of XAI with dermatologists or dermatopathologists?, Methods: Google Scholar, PubMed, IEEE Explore, Science Direct and Scopus were searched for peer-reviewed studies published between January 2017 and October 2021 applying XAI to dermatological images: the search terms histopathological image, whole-slide image, clinical image, dermoscopic image, skin, dermatology, explainable, interpretable and XAI were used in various combinations. Only studies concerned with skin cancer were included., Results: 37 publications fulfilled our inclusion criteria. Most studies (19/37) simply applied existing XAI methods to their classifier to interpret its decision-making. Some studies (4/37) proposed new XAI methods or improved upon existing techniques. 14/37 studies addressed specific questions such as bias detection and impact of XAI on man-machine-interactions. However, only three of them evaluated the performance and confidence of humans using CAD systems with XAI., Conclusion: XAI is commonly applied during the development of DNNs for skin cancer detection. However, a systematic and rigorous evaluation of its usefulness in this scenario is lacking., (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
24. Examination of Subungual Hematomas and Subungual Melanocytic Lesions by Using Optical Coherence Tomography and Dermoscopy.
- Author
-
Hobelsberger S, Laske J, Aschoff R, and Beissert S
- Subjects
- Humans, Male, Female, Dermoscopy methods, Tomography, Optical Coherence methods, Hematoma diagnostic imaging, Hematoma pathology, Nevus, Pigmented diagnosis, Skin Neoplasms pathology, Nail Diseases diagnostic imaging
- Abstract
Introduction: Examination of subungual pigmented lesions is sometimes a diagnostic challenge for clinicians., Objectives: The study was aimed to investigate characteristic patterns in optical coherence tomography (OCT) of subungual hematomas and determine distinctive features that can differentiate them from subungual melanocytic lesions., Methods: VivoSight® (Michelson Diagnostics, Maidstone, UK) was used to examine 71 subungual hematomas and 11 subungual melanocytic lesions in 69 patients (18 female and 51 male patients)., Results: On OCT, bleeding was related to sharply defined black sickle-shaped (p < 0.001) or globular regions (not significant [ns]) with a hyperreflective margin (0.002), a grey center (0.013), hyperreflective lines in the area (ns) or periphery (p = 0.031), peripheral fading (p = 0.029), and red dots in the area (p = 0.001). In the 1 case of melanoma in situ examined, we found curved vessels with irregular sizes and distribution on the dermis of the nailbed, while subungual hematomas and subungual benign nevi presented as clustered red dots and/or regularly distributed curved vessels., Conclusion: Our findings indicate that the use of OCT in addition to dermoscopy provides high-resolution optical imaging information for the diagnosis of subungual hematoma and facilitates the differential diagnosis of subungual hematomas and subungual melanocytic lesions., (© 2022 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2022
- Full Text
- View/download PDF
25. Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts.
- Author
-
Haggenmüller S, Maron RC, Hekler A, Utikal JS, Barata C, Barnhill RL, Beltraminelli H, Berking C, Betz-Stablein B, Blum A, Braun SA, Carr R, Combalia M, Fernandez-Figueras MT, Ferrara G, Fraitag S, French LE, Gellrich FF, Ghoreschi K, Goebeler M, Guitera P, Haenssle HA, Haferkamp S, Heinzerling L, Heppt MV, Hilke FJ, Hobelsberger S, Krahl D, Kutzner H, Lallas A, Liopyris K, Llamas-Velasco M, Malvehy J, Meier F, Müller CSL, Navarini AA, Navarrete-Dechent C, Perasole A, Poch G, Podlipnik S, Requena L, Rotemberg VM, Saggini A, Sangueza OP, Santonja C, Schadendorf D, Schilling B, Schlaak M, Schlager JG, Sergon M, Sondermann W, Soyer HP, Starz H, Stolz W, Vale E, Weyers W, Zink A, Krieghoff-Henning E, Kather JN, von Kalle C, Lipka DB, Fröhling S, Hauschild A, Kittler H, and Brinker TJ
- Subjects
- Automation, Biopsy, Clinical Competence, Deep Learning, Humans, Melanoma classification, Predictive Value of Tests, Reproducibility of Results, Skin Neoplasms classification, Dermatologists, Dermoscopy, Diagnosis, Computer-Assisted, Image Interpretation, Computer-Assisted, Melanoma pathology, Microscopy, Neural Networks, Computer, Pathologists, Skin Neoplasms pathology
- Abstract
Background: Multiple studies have compared the performance of artificial intelligence (AI)-based models for automated skin cancer classification to human experts, thus setting the cornerstone for a successful translation of AI-based tools into clinicopathological practice., Objective: The objective of the study was to systematically analyse the current state of research on reader studies involving melanoma and to assess their potential clinical relevance by evaluating three main aspects: test set characteristics (holdout/out-of-distribution data set, composition), test setting (experimental/clinical, inclusion of metadata) and representativeness of participating clinicians., Methods: PubMed, Medline and ScienceDirect were screened for peer-reviewed studies published between 2017 and 2021 and dealing with AI-based skin cancer classification involving melanoma. The search terms skin cancer classification, deep learning, convolutional neural network (CNN), melanoma (detection), digital biomarkers, histopathology and whole slide imaging were combined. Based on the search results, only studies that considered direct comparison of AI results with clinicians and had a diagnostic classification as their main objective were included., Results: A total of 19 reader studies fulfilled the inclusion criteria. Of these, 11 CNN-based approaches addressed the classification of dermoscopic images; 6 concentrated on the classification of clinical images, whereas 2 dermatopathological studies utilised digitised histopathological whole slide images., Conclusions: All 19 included studies demonstrated superior or at least equivalent performance of CNN-based classifiers compared with clinicians. However, almost all studies were conducted in highly artificial settings based exclusively on single images of the suspicious lesions. Moreover, test sets mainly consisted of holdout images and did not represent the full range of patient populations and melanoma subtypes encountered in clinical practice., Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: J.S.U. is on the advisory board or has received honoraria and travel support from Amgen, Bristol Myers Squibb, GSK, LEO Pharma, Merck Sharp and Dohme, Novartis, Pierre Fabre and Roche, outside the submitted work. M.G. has received speaker's honoraria and/or has served as a consultant and/or member of advisory boards for Almirall, Argenx, Biotest, Eli Lilly, Janssen Cilag, LEO Pharma, Novartis and UCB, outside the submitted work. H.A.H. worked as a consultant or received honoraria and travel support from Heine Optotechnik GmbH, JenLab GmbH, FotoFinder Systems GmbH, Magnosco GmbH, SciBase AB, Beiersdorf AG, Almirall Hermal GmbH and Galderma Laboratorium GmbH. V.M.R. is on the advisory board or has received honoraria or ownership in Inhabit Brands, Inc. unrelated to this work. Sondermann W. reports grants from medi GmbH Bayreuth, personal fees from Janssen, grants and personal fees from Novartis, personal fees from Lilly, personal fees from UCB, personal fees from Almirall, personal fees from LEO Pharma and personal fees from Sanofi Genzyme, outside the submitted work. H.P.S. is a shareholder of MoleMap NZ Limited and e-derm consult GmbH and undertakes regular tele-dermatological reporting for both companies. H.P.S. is a medical consultant for Canfield Scientific, Inc., MoleMap Australia Pty Ltd and Revenio Research Oy and a medical advisor for First Derm. M.L-V. has received speaker's honoraria and/or received grants and/or participated in clinical trials of AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen Cilag, LEO Pharma, Novartis and UCB, outside the submitted work. A.Z. has been an advisor and/or received speaker's honoraria and/or received grants and/or participated in clinical trials of AbbVie, Almirall, Amgen, Beiersdorf Dermo Medical, Bencard Allergy, Celgene, Eli Lilly, Janssen Cilag, LEO Pharma, Novartis, Sanofi-Aventis and UCB Pharma, outside the submitted work. Kittler H. received speaker's honoraria from FotoFinder Systems GmbH and received non-financial support from Heine Optotechnik GmbH, Derma Medical and 3Gen. T.J.B. reports owning a company that develops mobile apps, including the teledermatology services AppDoc (https://online-hautarzt.de) and Intimarzt (https://Intimarzt.de); Smart Health Heidelberg GmbH, Handschuhsheimer Landstr. 9/1, 69120 Heidelberg, https://smarthealth.de. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
26. A benchmark for neural network robustness in skin cancer classification.
- Author
-
Maron RC, Schlager JG, Haggenmüller S, von Kalle C, Utikal JS, Meier F, Gellrich FF, Hobelsberger S, Hauschild A, French L, Heinzerling L, Schlaak M, Ghoreschi K, Hilke FJ, Poch G, Heppt MV, Berking C, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Goebeler M, Krieghoff-Henning E, Hekler A, Fröhling S, Lipka DB, Kather JN, and Brinker TJ
- Subjects
- Humans, Benchmarking standards, Neural Networks, Computer, Skin Neoplasms classification
- Abstract
Background: One prominent application for deep learning-based classifiers is skin cancer classification on dermoscopic images. However, classifier evaluation is often limited to holdout data which can mask common shortcomings such as susceptibility to confounding factors. To increase clinical applicability, it is necessary to thoroughly evaluate such classifiers on out-of-distribution (OOD) data., Objective: The objective of the study was to establish a dermoscopic skin cancer benchmark in which classifier robustness to OOD data can be measured., Methods: Using a proprietary dermoscopic image database and a set of image transformations, we create an OOD robustness benchmark and evaluate the robustness of four different convolutional neural network (CNN) architectures on it., Results: The benchmark contains three data sets-Skin Archive Munich (SAM), SAM-corrupted (SAM-C) and SAM-perturbed (SAM-P)-and is publicly available for download. To maintain the benchmark's OOD status, ground truth labels are not provided and test results should be sent to us for assessment. The SAM data set contains 319 unmodified and biopsy-verified dermoscopic melanoma (n = 194) and nevus (n = 125) images. SAM-C and SAM-P contain images from SAM which were artificially modified to test a classifier against low-quality inputs and to measure its prediction stability over small image changes, respectively. All four CNNs showed susceptibility to corruptions and perturbations., Conclusions: This benchmark provides three data sets which allow for OOD testing of binary skin cancer classifiers. Our classifier performance confirms the shortcomings of CNNs and provides a frame of reference. Altogether, this benchmark should facilitate a more thorough evaluation process and thereby enable the development of more robust skin cancer classifiers., Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: J.S.U. is on the advisory board or has received honoraria and travel support from Amgen, Bristol Myers Squibb, GSK, Leo Pharma, Merck Sharp and Dohme, Novartis, Pierre Fabre and Roche, outside the submitted work. F.M. has received travel support or/and speaker's fees or/and advisor's honoraria from Novartis, Roche, BMS, MSD and Pierre Fabre and research funding from Novartis and Roche. S.H. reports advisory roles for or has received honoraria from Pierre Fabre Pharmaceuticals, Novartis, Roche, BMS, Amgen and MSD outside the submitted work. A.H. reports clinical trial support, speaker's honoraria or consultancy fees from the following companies: Amgen, BMS, Merck Serono, MSD, Novartis, OncoSec, Philogen, Pierre Fabre, Provectus, Regeneron, Roche, OncoSec, Sanofi Genzyme and Sun Pharma, outside the submitted work. W.S. reports grants from medi GmbH Bayreuth, personal fees from Janssen, grants and personal fees from Novartis, personal fees from Lilly, personal fees from UCB, personal fees from Almirall, personal fees from Leo Pharma and personal fees from Sanofi Genzyme, outside the submitted work. B.S. reports advisory roles for or has received honoraria from Pierre Fabre Pharmaceuticals, Incyte, Novartis, Roche, BMS and MSD, research funding from BMS, Pierre Fabre Pharmaceuticals and MSD and travel support from Novartis, Roche, BMS, Pierre Fabre Pharmaceuticals and Amgen, outside the submitted work. M.G. has received speaker's honoraria and/or has served as a consultant and/or member of advisory boards for Almirall, argenx, Biotest, Eli Lilly, Janssen Cilag, Leo Pharma, Novartis and UCB, outside the submitted work. T.J.B. reports owning a company that develops mobile apps including the teledermatology services AppDoc (https://online-hautarzt.net) and Intimarzt (https://intimarzt.de): Smart Health Heidelberg GmbH, Handschuhsheimer Landstr. 9/1, 69120 Heidelberg, https://smarthealth.de. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
27. Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification.
- Author
-
Höhn J, Krieghoff-Henning E, Jutzi TB, von Kalle C, Utikal JS, Meier F, Gellrich FF, Hobelsberger S, Hauschild A, Schlager JG, French L, Heinzerling L, Schlaak M, Ghoreschi K, Hilke FJ, Poch G, Kutzner H, Heppt MV, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Goebeler M, Hekler A, Fröhling S, Lipka DB, Kather JN, Krahl D, Ferrara G, Haggenmüller S, and Brinker TJ
- Subjects
- Adult, Age Factors, Aged, Databases, Factual, Female, Germany, Humans, Male, Melanoma classification, Middle Aged, Nevus classification, Predictive Value of Tests, Reproducibility of Results, Retrospective Studies, Sex Factors, Skin Neoplasms classification, Image Interpretation, Computer-Assisted, Melanoma pathology, Microscopy, Neural Networks, Computer, Nevus pathology, Skin Neoplasms pathology
- Abstract
Background: Clinicians and pathologists traditionally use patient data in addition to clinical examination to support their diagnoses., Objectives: We investigated whether a combination of histologic whole slides image (WSI) analysis based on convolutional neural networks (CNNs) and commonly available patient data (age, sex and anatomical site of the lesion) in a binary melanoma/nevus classification task could increase the performance compared with CNNs alone., Methods: We used 431 WSIs from two different laboratories and analysed the performance of classifiers that used the image or patient data individually or three common fusion techniques. Furthermore, we tested a naive combination of patient data and an image classifier: for cases interpreted as 'uncertain' (CNN output score <0.7), the decision of the CNN was replaced by the decision of the patient data classifier., Results: The CNN on its own achieved the best performance (mean ± standard deviation of five individual runs) with AUROC of 92.30% ± 0.23% and balanced accuracy of 83.17% ± 0.38%. While the classification performance was not significantly improved in general by any of the tested fusions, naive strategy of replacing the image classifier with the patient data classifier on slides with low output scores improved balanced accuracy to 86.72% ± 0.36%., Conclusion: In most cases, the CNN on its own was so accurate that patient data integration did not provide any benefit. However, incorporating patient data for lesions that were classified by the CNN with low 'confidence' improved balanced accuracy., Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Haferkamp S. reports advisory roles for or has received honoraria from Pierre Fabre Pharmaceuticals, Novartis, Roche, BMS, Amgen and MSD outside the submitted work. Hauschild A. reports clinical trial support, speaker's honoraria or consultancy fees from the following companies: Amgen, BMS, Merck Serono, MSD, Novartis, Oncosec, Philogen, Pierre Fabre, Provectus, Regeneron, Roche, OncoSec, Sanofi-Genzyme and Sun Pharma, outside the submitted work. BS reports advisory roles for or has received honoraria from Pierre Fabre Pharmaceuticals, Incyte, Novartis, Roche, BMS and MSD, research funding from BMS, Pierre Fabre Pharmaceuticals and MSD, and travel support from Novartis, Roche, BMS, Pierre Fabre Pharmaceuticals and Amgen, outside the submitted work. JSU is on the advisory board or has received honoraria and travel support from Amgen, Bristol Myers Squibb, GSK, LeoPharma, Merck Sharp and Dohme, Novartis, Pierre Fabre, Roche, outside the submitted work. WS received travel expenses for attending meetings and/or (speaker) honoraria from Abbvie, Almirall, Bristol-Myers Squibb, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi Genzyme and UCB outside the submitted work. FM has received travel support or/and speaker's fees or/and advisor's honoraria by Novartis, Roche, BMS, MSD and Pierre Fabre and research funding from Novartis and Roche. TJB reports owning a company that develops mobile applications (Smart Health Heidelberg GmbH, Handschuhsheimer Landstr. 9/1, 69120 Heidelberg, https://smarthealth.de). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
28. Implementation Science Meets Software Development to Create eHealth Components for an Integrated Care Model for Allogeneic Stem Cell Transplantation Facilitated by eHealth: The SMILe Study as an Example.
- Author
-
Leppla L, Hobelsberger S, Rockstein D, Werlitz V, Pschenitza S, Heidegger P, De Geest S, Valenta S, and Teynor A
- Subjects
- Female, Humans, Male, Middle Aged, Models, Organizational, Delivery of Health Care, Integrated organization & administration, Hematopoietic Stem Cell Transplantation, Implementation Science, Software, Telemedicine organization & administration
- Abstract
Purpose: To describe a process of creating eHealth components for an integrated care model using an agile software development approach, user-centered design and, via the Behavior Change Wheel, behavior theory-guided content development. Following the principles of implementation science and using the SMILe project (integrated care model for allogeneic stem cell transplantation facilitated by eHealth) as an example, this study demonstrates how to narrow the research-to-practice gap often encountered in eHealth projects., Methods: We followed a four-step process: (a) formation of an interdisciplinary team; (b) a contextual analysis to drive the development process via behavioral theory; (c) transfer of content to software following agile software development principles; and (d) frequent stakeholder and end user involvement following user-centered design principles., Findings: Our newly developed comprehensive development approach allowed us to create a running eHealth component and embed it in an integrated care model. An interdisciplinary team's collaboration at specified interaction points supported clear, timely communication and interactions between the specialists. Because behavioral theory drove the content development process, we formulated user stories to define the software features, which were prioritized and iteratively developed using agile software development principles. A prototype intervention module has now been developed and received high ratings on the System Usability Scale after two rounds of usability testing., Conclusions: Following an agile software development process, structured collaboration between nursing scientists and software specialists allowed our interdisciplinary team to develop meaningful, theory-based eHealth components adapted to context-specific needs., Clinical Relevance: The creation of high-quality, accurately fitting eHealth components specifically to be embedded in integrated care models should increase the chances of uptake, adoption, and sustainable implementation in clinical practice., (© 2020 The Authors. Journal of Nursing Scholarship published by Wiley Periodicals LLC on behalf of Sigma Theta Tau International.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.